Overview

• Peer-reviewed results report that 84% of participants could read letters, numbers and words with the PRIMA system, with an average gain of about five lines on a vision chart and 26 of 32 showing clinically meaningful acuity improvement at 12 months.
• The international PRIMAvera trial enrolled 38 people with geographic atrophy at 17 sites across five European countries, and many used the prosthetic vision at home for reading tasks.
• Safety findings include 26 significant procedure-related adverse events in 19 participants, mostly within two months of surgery, with the vast majority resolving and procedure-related issues subsiding by one year.
• The system couples a 2×2 mm wireless photovoltaic chip implanted under the retina with camera-equipped glasses that project near‑infrared images, which the chip converts to electrical pulses to stimulate remaining retinal cells.
• Current performance provides low-resolution, black‑and‑white central vision that requires months of rehabilitation; clinicians describe meaningful functional gains, and the device’s developer has applied for clinical use authorization.